Worldwide Cancer Vaccines Industry to 2026 - Featuring AstraZeneca, GlaxoSmithKline and Moderna Among Others - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Cancer Vaccines Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
The cancer vaccines market is projected to register a CAGR of 13.24% during the forecast period, with a revenue of approximately USD 4,825.61 million in 2020 and expected to reach USD 10,175.41 million by 2026.
- Anixa Biosciences, Inc.
- AstraZeneca PLC
- Bristol Myers Squibb Company
- F. Hoffmann-La Roche AG (Genentech)
- GlaxoSmithKline PLC
- Merck & Co. Inc.
- OSE Immunotherapeutics
- Sanofi SA
- Dendreon Pharmaceuticals LLC.
- Moderna, Inc.
- Vaccitech Limited
- eTheRNA immunotherapies
Key Market Trends
Recombinant Cancer Vaccines are Expected to a Hold Significant Market Share in the Cancer Vaccines Market
A recombinant vaccine is a vaccine produced through recombinant DNA technology. This includes DNA encoding an antigen, which stimulates an immune response into mammalian cells, expressing the antigen in these cells and then purifying it from them. Many different viruses have been genetically modified to express tumour-associated antigens (TAA) for intramuscular or subcutaneous injection.
Poxviruses have several beneficial features as vectors for cancer vaccines, including broad cell tropism, potent immunogenicity, and pre-existing neutralizing immunity, only in those patients who received the vaccinia virus (the smallpox vaccine). Vaccinia virus, fowlpox virus, and canarypox virus have been investigated clinically for cancer vaccination.
Furthermore, numerous studies are being conducted in the field of viral recombinant cancer vaccines, which may reap positive results in future, primarily related to cancer vaccination. This is expected to aid the market's growth. For instance, In July 2019, Oxford Vacmedix UK Limited (OVM), a UK-based biopharma company collaborated and issued Innovate UK grant to CHAIN Biotechnology Ltd and the University of Oxford to develop OVM-100, a recombinant overlapping peptide (ROP) HPV vaccine targeted at cervical cancer.
However, the recent COVID 19 pandemic has posed a significant negative impact on the respective segment by delaying the development activities of recombinant cancer vaccines.
North America Dominates the Market Over the Forecast Period
North America is expected to grow due to the high prevalence of cancer, along with developed healthcare infrastructure in the region. The United States has a better healthcare infrastructure than most developed countries. The National Cancer Institute (NCI) stated that the national spending on cancer care is expected to reach USD 156 billion by 2020.
According to the estimates of the GLOBOCAN, in 2020, an estimated 1,95,499 new cases of cancer were diagnosed in Mexico, and 90,222 people died from the disease. The rising number of cancer cases are creating opportunities for market players.
The major market players are focusing on R&D activities to bring new and reliable treatments to the market. In December 2020, Anixa Biosciences a San Jose, California based biotech company in partnership with Cleveland Clinic received USFDA investigational new drug application for its new breast cancer vaccine technology developed by Cleveland Clinic immunologist Dr Vincent Tuohy, and his research team to start the first human clinical trials.
Providence Therapeutics is a Toronto based clinical stage biotechnology company that develops cancer vaccines for human use. Currently company is developing a personalized mRNA cancer vaccine designed to generate strong T cell responses that aim to kill cancer cells and destroy tumors in ovarian cancer, breast cancer and brain cancer.
Key Topics Covered:
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Cancer
4.2.2 Rising Investments and Government Funding in the Development of Cancer Vaccines
4.2.3 Technological Developments in Cancer Vaccines
4.3 Market Restraints
4.3.1 Stringent Regulatory Guidelines and Longer Timelines Required for Manufacturing Process
4.3.2 Presence of Alternative Therapies
4.4 Porter's Five Forces Analysis
5 MARKET SEGMENTATION
5.1 By Technology
5.2 By Treatment Method
5.3 By Application
6 COMPETITIVE LANDSCAPE
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/2zamu8
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900